Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

or

Watchlist | Portfolio | Dashboard

quotes
- Price Overview
- Performance Report
charts
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Regulus: Q2 Earnings Snapshot AP - Thu Aug 8, 4:19PM CDT

Regulus: Q2 Earnings Snapshot

Regulus: Q1 Earnings Snapshot AP - Thu May 9, 4:16PM CDT

Regulus: Q1 Earnings Snapshot

Regulus: Q4 Earnings Snapshot AP - Thu Mar 21, 3:22PM CDT

Regulus: Q4 Earnings Snapshot

Regulus: Q3 Earnings Snapshot AP - Thu Nov 9, 2023

Regulus: Q3 Earnings Snapshot

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire - Wed Sep 13, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Regulus: Q2 Earnings Snapshot AP - Tue Aug 8, 2023

Regulus: Q2 Earnings Snapshot

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire - Tue Aug 8, 2023

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Use your up/down arrows to move through the symbols.

Free Barchart Webinar